UPDATE: CRT Capital Initiates Coverage on OncoGenex
February 27, 2014 at 11:06 AM EST
CRT Capital Thursday morning ratings report included a coverage initiation by analyst Arlinda Lee on Oncogenex Pharmaceuticals (NASDAQ: OGXI ) with a Buy rating and price target of $20. The highlight for OGXI includes phase 3 trials of Curtisen and subsequent partnership with Teva, along with phase 2 trials of
